39
Revolutionary New Approach to ECG Management in Clinical Trials
ERT announced the launch of Centralised Cardiac Safety 2.0, a portfolio of new solutions that enable a significant new approach to cardiac safety in clinical trials. These new solutions overcome many of the perceived barriers to centralising all ECGs in clinical trials. ERT’s aim is to improve the science of cardiac safety while helping sponsors reduce overall costs with the adoption of a fully centralised approach. ERT’s Centralised Cardiac Safety 2.0 utilises newly developed software technology, within its best in class EXPERT operating platform, which improves data quality, reduces the investigator workload and improves the overall user experience at the investigative site. This technology enables the collection of real time, consistent, quality information easing site operations for all stakeholders and delivering better value to biopharmaceutical companies.
To further enable trial sponsors to take full advantage of the benefits offered by this centralised ECG model, innovative new instruments are necessary to provide improved accuracy, reliability, space efficiency and cost effectiveness. As part of the Centralised Cardiac Safety 2.0 solution, ERT has also introduced ELI-PC under exclusive license from Mortara Instrument. This will substantially reduce the ECG equipment and systems interface costs associated with a centralised approach. This small hand-held ECG collection device will make it easier for companies to adopt a centralised system as it interacts seamlessly and automatically with the central database, dramatically reducing both site workload and the volume of queries generated. This reduction in queries will accelerate trial timelines in the same way that EDC has improved the data collection process in clinical trials in recent years. Integration of this new ECG machine into computer systems will enable key information, such as patient demographics, to be automatically downloaded before a trial, saving staff time and costs associated with trial set-up.
Circle no. 115
New Range of Protective Eyewear
Draeger has launched a state-of-the-art range of protective spectacles and goggles. Joining Draeger’s extensive range of personal protective equipment (PPE), the new Draeger X-pect 8000 eyewear collection combines a stylish finish with optimum safety and maximum wearer comfort. Suitable for use with other forms of PPE such as ear defenders or respiratory protection, the range comprises different models to suit a wide variety of applications.
Featuring anti-scratch and anti-fog coatings to ensure clear vision in even the most demanding situations, the Draeger X-pect 8000 Series offers the highest UV protection and the best optical class category for continuous work. Ergonomically designed to provide both comfort and an unrestricted field of vision, these robust yet lightweight eye protectors also meet the requirements of EN 166:2001.
Designed for use with prescription glasses, the strong, polycarbonate Cover Spectacles feature a universal nose bridge and a large mono lens for a wide field of vision. The range includes the Draeger X-pect 8110 and the classic design of the Draeger X-pect 8120.
The Draeger X-pect range of Spectacles features a curved, wrap-around design to ensure a large field of vision, optimum wearer comfort and effective lateral protection. Benefiting from the strength and durability of 100% polycarbonate materials, these attractive spectacles also incorporate anti-scratch and anti- fog coatings. Range includes the unisex Draeger X-pect 8310; the new generation Draeger X-pect 8320; the Draeger X-pect 8330; and the sporty Draeger X-pect 8340. The wrap-around design of the Draeger X-pect range of Goggles brings a perfect fit, a large field of vision and optimum protection to the wearer. The soft, flexible PVC frame of the Draeger X-pect 8515 ensures the best possible fit, while the trendy Draeger X-pect 8520 heralds a new generation in safety goggles.
Circle no. 116
Circle no. 117
Spotlight
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
